



Patent  
242/020

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Cynthia K. French et al

Serial No.: 09/680,121

Group No.: 1642

Filed: October 4, 2000

Examiner: Gary B. Nickol

For: PROSTATE CANCER-SPECIFIC MARKER

RECEIVED

NOV 26 2002

TECH CENTER 1600/2900

COMMISSIONER FOR PATENTS  
Washington, D.C. 20231

TRANSMITTAL LETTER

1. Transmitted herewith is a Terminal Disclaimer in reference to the above-captioned application.
2. Other Papers Enclosed:

Terminal Disclaimer Fee \$ 55.00 Charge Orrick, Herrington & Sutcliffe LLP Deposit Account  
No. 150665

37 C.F.R. § 1.17(r) Fee \$

37 C.F.R. § 1.17(m) Fee \$

STATUS

3. Applicant is:  a small entity  other than a small entity  
A verified statement claiming small entity status is:  
 attached  already filed


---

CERTIFICATE OF MAILING (37 C.F.R. §1.10)

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as 'Express Mail Post Office To Addressee' in an envelope addressed to the Commissioner for Patents, Washington, D.C. 20231.

EV 207872382 US  
Express Mail Label No.

November 20 2002  
Date of Deposit

Lynne Fulmer  
Name of Person Mailing Paper  
  
Signature of Person Mailing Paper

## FEE PAYMENT

- Attached is our check in the sum of \$\_\_\_\_\_.
- Charge Orrick, Herrington & Sutcliffe LLP Deposit Account No. 150665  
the sum of \$ 55.00 .

## FEE DEFICIENCY


7. Authorization to charge additional fees and instructions as to over payment:

The Commissioner is hereby authorized to charge any additional fees which may be required or credit any over payment Charge Orrick, Herrington & Sutcliffe LLP Deposit Account No. 150665

Respectfully submitted,

ORRICK, HERRINGTON & SUTCLIFFE LLP

By

  
Kurt T. Mulville  
Reg. No. 37,194

Dated: November 20, 2002

KTM/lf  
4 Park Plaza, Suite 1600  
Irvine, CA 92614  
949/567-6700 X 7740 Telephone  
949/567-6710 Facsimile

#13



Patent  
270/228

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

**Cynthia K. French, et al.**

Serial No.: 09/680,121

Filed: October 4, 2000

For: **PROSTATE CANCER-SPECIFIC  
MARKER**

) Group Art Unit: 1642

) Examiner: Gary B. Nickol

**RECEIVED**

NOV 26 2002

TECH CENTER 1600/2900

**TERMINAL DISCLAIMER**

Commissioner for Patents  
Washington, D.C. 20231

Sir:

I, Kurt T. Mulville, represent that I am an attorney of record for the above-identified application. The above-identified invention has been assigned to DIAGNOSTIC PRODUCTS CORPORATION. DIAGNOSTIC PRODUCTS CORPORATION is the owner of 100% interest in the above-identified invention. DIAGNOSTIC PRODUCTS CORPORATION is owner of 100% interest in United States Patent No. 6,218,523, issued April 17, 2001.

Assignee hereby disclaims the terminal part of any patent granted on the above-identified application which would extend beyond the statutory expiration date of U. S. Patent No. 6,218,523.

**CERTIFICATE OF MAILING (37 C.F.R. §1.10)**

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as 'Express Mail Post Office To Addressee' in an envelope addressed to the Commissioner for Patents, Washington, D.C. 20231.

EV 207872382 US  
Express Mail Label No.

November 20 2002  
Date of Deposit  
DOCSOC1:130431.1  
L03584-02702282 K2M

Lynne Fulmer

Name of Person Mailing Paper

Lynne Fulmer

Signature of Person Mailing Paper

Patent  
Attorney Docket: 270/228

Moreover, assignee hereby agrees that any patent so granted on the above-identified application shall be enforceable only for and during such period that the legal title to said patent shall be the same as the legal title to United States Patent No. 6,218,523, this agreement to run with any patent granted on the above-identified application and to be binding upon assignee, successors, or assigns.

Assignee does not disclaim any terminal part of any patent granted on the above-identified application prior to the expiration date of the full statutory term of United States Patent No. 6,218,523 in the event that it later expires for failure to pay a maintenance fee, is held unenforceable, is found invalid, is statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. § 1.312(a), has all claims cancelled by a reexamination certificate, or is otherwise terminated prior to expiration of its statutory term as presently shortened by any terminal disclaimer, except for the separation of legal title stated above.

Respectfully submitted,

ORRICK, HERRINGTON & SUTCLIFFE LLP

By: 

Kurt T. Mulville  
Reg. No. 37,194

Dated: November 20, 2002

4 Park Plaza, Suite 1600  
Irvine, CA 92614  
949/567-6700 X 7740 Telephone  
949/567-6710 Facsimile